PMID- 30204739
OWN - NLM
STAT- MEDLINE
DCOM- 20190305
LR  - 20190305
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 44
IP  - 12
DP  - 2018 Dec
TI  - Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment of 
      Upper Facial Lines.
PG  - 1555-1564
LID - 10.1097/DSS.0000000000001679 [doi]
AB  - BACKGROUND: Botulinum toxins are the treatment of choice for wrinkles in the 
      upper third of the face. OBJECTIVE: The purpose of this study was to evaluate the 
      efficacy, safety, and subject satisfaction of abobotulinumtoxinA (ABO) for 
      treatment of upper facial lines. MATERIALS AND METHODS: Subjects aged 35 to 50 
      years with moderate-to-severe upper facial lines were included in this study. 
      Subjects received a maximum of 125 s.U. ABO in at least 2 indications with 
      optional touch-up after 2 weeks. Assessments included wrinkle severity, global 
      aesthetic improvement, subject satisfaction, and adverse events (AEs) 1, 3, and 6 
      months after treatment. RESULTS: At Month 1, 100, 94, and 93% of subjects were 
      responders in dynamic glabellar, lateral canthal, and forehead lines, 
      respectively. All subjects were improved 1 month after treatment, and the 
      majority of the subjects were still improved after 6 months. After treatment, 
      most subjects were satisfied with the appearance of their face, felt better about 
      themselves, and agreed that the treatment made them look the way they feel. Seven 
      subjects (22%) had 8 ABO-related AEs (mild-moderate); headache was most commonly 
      reported (9%). CONCLUSION: AbobotulinumtoxinA effectively treated upper facial 
      lines, with high patient satisfaction. Treatment was generally well-tolerated.
FAU - Hexsel, Doris
AU  - Hexsel D
AD  - Brazilian Center for Studies in Dermatology, Porto Alegre, RS, Brazil.
FAU - Cartier, Hugues
AU  - Cartier H
AD  - Centre Medical Saint-Jean, Arras, France.
FAU - Heden, Per
AU  - Heden P
AD  - Akademikliniken, Stockholm, Sweden.
FAU - Delmar, Henry
AU  - Delmar H
AD  - MEDITI -Clinique Science et Beaute, Juan-les-Pins, France.
FAU - Bergentz, Per
AU  - Bergentz P
AD  - Akademikliniken, Stockholm, Sweden.
FAU - Camozzato, Fernanda
AU  - Camozzato F
AD  - Brazilian Center for Studies in Dermatology, Porto Alegre, RS, Brazil.
FAU - Siega, Carolina
AU  - Siega C
AD  - Brazilian Center for Studies in Dermatology, Porto Alegre, RS, Brazil.
FAU - Skoglund, Cecilia
AU  - Skoglund C
AD  - Galderma, Uppsala, Sweden.
FAU - Edwartz, Carolina
AU  - Edwartz C
AD  - Galderma, Uppsala, Sweden.
FAU - Rees, Diane
AU  - Rees D
AD  - Zenith Healthcare Communications Ltd, Chester, Cheshire, United Kingdom.
FAU - Kestemont, Philippe
AU  - Kestemont P
AD  - MEDITI -Clinique Science et Beaute, Juan-les-Pins, France.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Acetylcholine Release Inhibitors)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
RN  - EC 3.4.24.69 (abobotulinumtoxinA)
SB  - IM
MH  - Acetylcholine Release Inhibitors/adverse effects/*therapeutic use
MH  - Adult
MH  - Botulinum Toxins, Type A/adverse effects/*therapeutic use
MH  - *Cosmetic Techniques
MH  - Esthetics
MH  - Female
MH  - Forehead
MH  - Headache/chemically induced
MH  - Humans
MH  - Lacrimal Apparatus
MH  - Male
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - Self Concept
MH  - Single-Blind Method
MH  - Skin Aging/*drug effects
MH  - Time Factors
EDAT- 2018/09/12 06:00
MHDA- 2019/03/06 06:00
CRDT- 2018/09/12 06:00
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2019/03/06 06:00 [medline]
PHST- 2018/09/12 06:00 [entrez]
AID - 10.1097/DSS.0000000000001679 [doi]
PST - ppublish
SO  - Dermatol Surg. 2018 Dec;44(12):1555-1564. doi: 10.1097/DSS.0000000000001679.